<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">19</article-id><article-id pub-id-type="publisher-id">2008MOLVIS0412</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Common variation in the <italic>SERPING1</italic> gene is not associated with age-related macular degeneration in two independent groups of subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Kyu Hyung</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Euijung</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tosakulwong</surname><given-names>Nirubol</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yanhong</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Edwards</surname><given-names>Albert O.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Ophthalmology, Mayo Clinic, Rochester, MN</aff><aff id="aff2"><label>2</label>Department of Ophthalmology, Seoul National University, Bundang Hospital, Gyeonggi, Korea</aff><aff id="aff3"><label>3</label>Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN</aff><aff id="aff4"><label>4</label>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Albert O. Edwards, M.D., Ph.D., Department of Ophthalmology, The Mayo Clinic, 200 First Street SW, Rochester, MN, 55905; Phone: (507) 284-2787; FAX: (507) 284-4612; email: <email xlink:href="edwardslab@mayo.edu">edwardslab@mayo.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>1</month><year>2009</year></pub-date><volume>15</volume><fpage>200</fpage><lpage>207</lpage><history><date date-type="received"><day>17</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2009</year></date></history><permissions><copyright-year>2009</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>Common genetic variation in the complement component 1 inhibitor gene (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&#x00026;cmd=retrieve&#x00026;list_uids=710"><italic>SERPING1</italic></ext-link>) was recently reported to increase the risk of developing age-related macular degeneration (AMD). This study was performed to replicate the association between <italic>SERPING1</italic> and AMD.</p></sec><sec sec-type="methods"><title>Methods</title><p>Seven single nucleotide polymorphisms (SNPs) tagging common haplotypes across <italic>SERPING1</italic> were genotyped on 786 (The Mayo Clinic) subjects and the association with AMD studied using single SNP and haplotype association analyses. The SNP in intron 6 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link>) previously reported to increase the risk of AMD was studied in an additional 1,541 subjects from the Age-Related Eye Disease Study (AREDS). Association with specific subtypes of AMD and interaction with four other loci: complement factor H (<italic>CFH</italic>), age-related maculopathy susceptibility 2 (<italic>ARMS2</italic>/<italic>LOC387715</italic>), High Temperature Requirement Factor A1 (<italic>HTRA1</italic>), complement factor B/complement component 2 (<italic>CFB/C2</italic>), and complement component 3 (<italic>C3</italic>) involved in AMD was explored.</p></sec><sec><title>Results</title><p>The seven tag-SNPs were not associated with AMD in the Mayo subjects (p=0.13&#x02013;0.70) and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> was also not associated with AMD in the Mayo or AREDS subjects (p=0.44&#x02013;0.45). Evaluation of haplotypes across <italic>SERPING1</italic> did not reveal association with AMD (p=0.14&#x02013;0.97). SNPs were not associated with AMD subtypes (early, geographic atrophy, or exudation). No interaction with other AMD risk variants was observed.</p></sec><sec><title>Conclusions</title><p>We were unable to replicate the reported association between <italic>SERPING1</italic> and AMD in two independent groups of subjects.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Age related macular degeneration (AMD) is a leading cause of irreversible loss of vision in older individuals [<xref ref-type="bibr" rid="r1">1</xref>]. Both genetic and cell biologic analyses support a role for dysregulation of innate immunity in the pathogenesis of AMD. Extensive deposition of innate immunity proteins at the level of Bruch&#x02019;s membrane [<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r3">3</xref>] in AMD patients has been consistently observed. Genetic variants in complement pathway genes including complement factor H (<italic>CFH)</italic> [<xref ref-type="bibr" rid="r4">4</xref>-<xref ref-type="bibr" rid="r6">6</xref>], complement factor B (<italic>CFB)/</italic>complement component 2 <italic>(C2)</italic> [<xref ref-type="bibr" rid="r7">7</xref>], and complement component 3 (<italic>C3)</italic> [<xref ref-type="bibr" rid="r8">8</xref>-<xref ref-type="bibr" rid="r11">11</xref>] are established risks for developing AMD. The association between AMD and genetic variation in these loci has been extensively replicated as recently reviewed [<xref ref-type="bibr" rid="r12">12</xref>]. Many other common genetic variants have been proposed for AMD. However, review of a partial list shows that they do not yet have sufficient support due to the absence of replication studies [<xref ref-type="bibr" rid="r13">13</xref>-<xref ref-type="bibr" rid="r20">20</xref>] or failure to consistently replicate the genetic association in independent groups of subjects [<xref ref-type="bibr" rid="r21">21</xref>-<xref ref-type="bibr" rid="r29">29</xref>]. Thus, at this time there is strong evidence for the involvement of genetic variation in genes of the alternative pathway of complement and one additional locus (<italic>LOC387715/</italic>High Temperature Requirement Factor A1 [<italic>HTRA1</italic>]) on chromosome 10q26 [<xref ref-type="bibr" rid="r30">30</xref>,<xref ref-type="bibr" rid="r31">31</xref>].</p><p>Recently, there has been interest in exploring the genes involved in classical complement activation initiated by antibody-antigen interactions. Evidence for a possible role of the classical complement pathway comes from the observation of anti-retinal antibodies in patients with AMD [<xref ref-type="bibr" rid="r32">32</xref>-<xref ref-type="bibr" rid="r35">35</xref>], animal models with AMD-like pathology [<xref ref-type="bibr" rid="r36">36</xref>], and expression of these proteins in the aging retina and retinal pigment epithelium (RPE) [<xref ref-type="bibr" rid="r37">37</xref>].</p><p>The complement component 1 (C1) inhibitor is a key regulator of the classical pathway and has been reported to down-regulate the alternative pathway in vitro by binding to C3b and inhibiting binding of complement factor B to C3b [<xref ref-type="bibr" rid="r38">38</xref>]. The C1 inhibitor has sequence homology with serine protease inhibitors (SERPIN) and inhibits activation of the classical and lectin compliment pathways by inhibiting the protease activity of complement component 1, r subcomponent (C1r), complement component 1, s subcomponent (C1s), and mannan-binding lectin serine peptidase 2 (MASP-2) [<xref ref-type="bibr" rid="r39">39</xref>,<xref ref-type="bibr" rid="r40">40</xref>]. The C1 inhibitor also regulates vascular permeability by inhibiting proteases that generate bradykinin [<xref ref-type="bibr" rid="r40">40</xref>], as manifested when deficiency of C1 inhibitor results in hereditary angioedema [<xref ref-type="bibr" rid="r41">41</xref>-<xref ref-type="bibr" rid="r43">43</xref>]. Thus, C1 inhibitor is an excellent candidate gene for involvement in AMD and retinal aging.</p><p>Since the discovery of the association between AMD and variants in <italic>CFH</italic>, the systematic study of other genes regulating or involved in the alternative pathway of complement activation has been productive (e.g., the study of <italic>CFB/C2</italic>, <italic>C3</italic> [<xref ref-type="bibr" rid="r7">7</xref>-<xref ref-type="bibr" rid="r11">11</xref>]). The systematic study of other genes involved in innate immunity is ongoing in several laboratories. A recent study reported a protective effect on AMD for the minor allele of a SNP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link>) within intron 6 of the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&#x00026;cmd=retrieve&#x00026;list_uids=710"><italic>SERPING1</italic></ext-link> gene encoding the C1 inhibitor [<xref ref-type="bibr" rid="r13">13</xref>]. The purpose of this study was to replicate the association between <italic>SERPING1</italic> and AMD in two independent groups of subjects. We performed a systematic analysis of all common haplotypes (ancestral segments of DNA inherited as a block in a population) across the <italic>SERPING1</italic> locus and identified no evidence for association with AMD.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>The study was approved by the institutional review board of the Mayo Clinic (Rochester, MN) and written informed consent was obtained from all subjects. The Mayo subjects were composed of 786 Caucasian individuals (476 AMD cases, 310 controls without AMD). Subjects and cases were obtained from the same eye clinics of participating physicians. Diagnosis was determined by review of fundus photographs as described previously [<xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r44">44</xref>,<xref ref-type="bibr" rid="r45">45</xref>]. Briefly, all subjects diagnosed with AMD had large drusen (&#x02265;125 microns) with sufficient drusen area to fill a 700 micron circle or more advanced findings. Controls had 5 or fewer hard drusen (&#x0003c;63 microns) without pigment changes or more advanced findings. Geographic atrophy and exudation were defined using the Wisconsin age-related maculopathy grading system [<xref ref-type="bibr" rid="r46">46</xref>]. The Mayo subjects have been graded multiple independent times by Dr. Edwards and were recently re-graded by Dr. Park. Replication studies were performed on 1,541 Caucasian subjects (1,241 with AMD and 300 controls without AMD) from the Age-Related Eye Disease Study (AREDS) that were graded as reported previously [<xref ref-type="bibr" rid="r47">47</xref>]. The final AREDS phenotype grade was used. All control grades (controls and control questionable 1&#x02013;4) were treated as controls. Early AMD consisted of all grades of large drusen (large drusen and large drusen questionable 1&#x02013;3). Review of genotype frequencies for the control questionable and large drusen questionable AREDS subjects at known AMD risk variants showed that the questionable groups closely matched their assigned group (e.g., for the <italic>C3</italic> SNP <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2230199">rs2230199</ext-link>, genotype frequencies were within 1% when the questionable control or large drusen categories were excluded). Further, the maximal difference in genotype frequencies for the <italic>SERPING1</italic> SNP <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> was 0.03.</p><p>Advanced AMD AREDS subjects consisted of all advanced AMD grades (questionable advanced, neovascular, geographic atrophy, and both neovascular and geographic atrophy). Mayo or AREDS subjects with both neovascular and geographic atrophy were included in the analysis for each subtype, except when the analytical model required a unique grade. When a unique grade for each subject was required, the subjects graded both were added to the grade with a smaller number of subjects (geographic atrophy) to increase power. Individual SNP analyses were done with and without both, and no differential effect was observed. Eighty-seven subjects with the questionable advanced AMD grade only were used for any AMD versus control analyses. Note that the number of subjects shown in the tables may be less than the total number of subjects available for study, due to failed genotyping. No detectable substructure has been observed within the Mayo subjects that might inflate case-control statistics, and the small amount of sub-structure within the AREDS subjects had no effect on the individual SNP case-control statistics. Demographic and phenotypic information for the Mayo and AREDS subjects is provided in <xref ref-type="table" rid="t1">Table 1</xref>.</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Demographic and phenotypic features of the Mayo and AREDS subjects</title></caption><table frame="hsides" rules="groups"><col width="77" span="1"/><col width="54" span="1"/><col width="75" span="1"/><col width="81" span="1"/><col width="62" span="1"/><col width="72" span="1"/><col width="90" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><bold>Category</bold><hr/></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Mayo subjects</bold></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><bold>AREDS subjects</bold></th></tr></thead><tbody><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1"><bold>Number</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Age (Mean&#x000b1;SD)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Male:Female ratio</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Number</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Age (Mean&#x000b1;SD)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Male:Female ratio</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Control subjects<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">310<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69.5&#x000b1;8.2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.83<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">77.6&#x000b1;4.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.79<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AMD subjects*<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">476<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">76.9&#x000b1;9.6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.55<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1241<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">79.9&#x000b1;5.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.68<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Early AMD<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">218<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">73.7&#x000b1;10.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.46<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">583<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">79.0&#x000b1;4.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.65<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exudation<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">161<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">79.2&#x000b1;8.7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.59<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">324<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80.6&#x000b1;5.0<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.76<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Geographic atrophy**</td><td valign="top" align="center" rowspan="1" colspan="1">97</td><td valign="top" align="center" rowspan="1" colspan="1">80.2&#x000b1;6.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.70</td><td valign="top" align="center" rowspan="1" colspan="1">247</td><td valign="top" align="center" rowspan="1" colspan="1">80.8&#x000b1;5.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.65</td></tr></tbody></table><table-wrap-foot><p>*Eighty-seven AREDS subjects with the &#x0201c;questionable advanced age-related macular degeneration (AMD)&#x0201d; grade were used as described in Methods, but are not included in this table. **29 Mayo subjects and 85 AREDS subjects who had both geographic atrophy and exudative AMD (category &#x0201c;Both&#x0201d;) were included in the geographic atrophy group as described in the Methods. Abbreviations: SD is standard deviation.</p></table-wrap-foot></table-wrap></sec><sec><title>Selection of tag and functional SNPs</title><p>SNPs genotyped in the international haplotype map (<ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org/">HapMap</ext-link>) [<xref ref-type="bibr" rid="r48">48</xref>] were used to select tag SNPs. SNPs across <italic>SERPING1</italic> including 5 kb up and downstream were evaluated for linkage disequilibrium (LD) using ldSelect [<xref ref-type="bibr" rid="r49">49</xref>] and a custom algorithm for tag-SNP selection was developed so that a single tag SNP would be selected for each LD bin. Only those SNPs deemed candidate tag-SNPs by ldSelect with a minor allele frequency (MAF) of greater than or equal to 0.05 were considered for further selection. Tag-SNPs were ultimately selected based upon a functional ranking system wherein non-synonymous coding SNPs were preferentially selected among the tag-SNP candidates in each LD bin, followed by synonymous coding SNPs, SNPs from 5&#x02032; untranslated regions (UTRs), SNPs from 3&#x02032; UTRs, and finally SNPs from intronic regions. Seven SNPs were required to tag the <italic>SERPING1</italic> haplotypes and were selected for genotyping.</p></sec><sec><title>Genotyping</title><p>The seven tag-SNPs were genotyped on genomic DNA extracted from peripheral blood leukocytes using TaqMan assays. Clustering of genotypes was inspected for separation between genotypes and accuracy of genotype calls. Quality control for genotype call was assessed by concordance for the control CEPH trio DNA replicates and two sample replicates within each 96 well plate. Randomly selected cases (25 subjects) and controls (25 subjects) were subjected to bi-directional DNA sequencing to determine the accuracy of genotyping with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> in a masked fashion.</p></sec><sec><title>Statistics</title><p>Upon receipt of genotype intensities and processing as described above, all SNPs were noted to be in Hardy&#x02013;Weinberg equilibrium. Single SNP analyses on genotype distributions were performed in SAS version 8 (SAS Institute, Cary, NC) using logistic regression assuming a log-additive genetic model where SNPs were coded as 0, 1, or 2 for the number of minor alleles and the corresponding p-values were calculated based on the score test statistics. Fisher&#x02019;s exact tests were also performed on genotype distributions. Haplotype analyses were completed using the score test that consisted of the seven SNPs across <italic>SERPING1.</italic> We also performed haplotype analysis with a 3-SNP-sliding-window approach, as implemented in haplo.stats [<xref ref-type="bibr" rid="r50">50</xref>] using R statistical software. Interaction effect between <italic>SERPING1</italic> SNPs and smoking status (defined as ever, never) on AMD status was evaluated under a log-additive model with logistic regression using two main effect terms (genotype for each SNP and smoking status) and their interaction term, and assessed by a likelihood ratio test. We also evaluated interaction between <italic>SERPING1</italic> SNPs and other major genetics risks for AMD including complement factor H (<italic>CFH</italic>, Y402H), <italic>LOC387715</italic>/<italic>HTRA1</italic> (tagging SNP A69S), <italic>CFB/C2</italic> (<italic>CFB</italic>, L9H; <italic>C2</italic>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=547154">rs547154</ext-link>), and <italic>C3</italic> (R102G and P314L). To investigate the effect of the seven SNPs of <italic>SERPING1</italic> including <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> on AMD subtypes, likelihood ratio tests were performed considering controls as baseline. Haplotype analyses for AMD subtypes were also performed using a likelihood ratio test. Age is confounded with diagnosis (i.e., the cases are older than the controls), thus correction for age might reduce any detectable genetic effect and was not employed. Nominal p-values are reported.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Association between individual SNPs and AMD in the Mayo subjects</title><p>None of the seven SNPs tagging <italic>SERPING1</italic> haplotypes (including <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link>) were associated with AMD subjects compared to controls without AMD (<xref ref-type="table" rid="t2">Table 2</xref>). Because of the previously reported association between <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> and AMD, we sought to determine the accuracy of genotyping using DNA sequencing. The genotype for 50 subjects determined by DNA sequencing was in complete agreement with the TaqMan assay genotype calls. Thus, the absence of association could not be explained by inaccurate genotyping.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Distribution of genotypes for the seven tag-SNPs across <italic>SERPING1</italic> and their association with AMD in the Mayo subjects</title></caption><table frame="hsides" rules="groups"><col width="61" span="1"/><col width="56" span="1"/><col width="58" span="1"/><col width="62" span="1"/><col width="81" span="1"/><col width="60" span="1"/><col width="65" span="1"/><col width="54" span="1"/><col width="54" span="1"/><col width="54" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>SNP</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Function</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Location</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Minor allele frequency</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Hardy&#x02013;Weinberg equilibrium (p-value)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Genotype</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Number AMD Cases (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Number controls (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Fisher p-value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Log-additive p-value</bold></th></tr></thead><tbody><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2509897">rs2509897</ext-link><hr/></td><td rowspan="3" valign="top" align="center" colspan="1">2.4 K upstream<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">57119193<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.36<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.87<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">197 (42)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">122 (39)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.66<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.52<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">204 (44)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">146 (47)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">64 (14)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42 (14)<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511990">rs2511990</ext-link><hr/></td><td rowspan="3" valign="top" align="center" colspan="1">2.3 K upstream<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">57119284<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.5<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">126 (27)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80 (26)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.72<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.51<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">223 (48)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">141 (46)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">116 (25)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">84 (28)<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3758919">rs3758919</ext-link><hr/></td><td rowspan="3" valign="top" align="center" colspan="1">2.2 K upstream<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">57119379<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.11<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.92<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">382 (81)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">236 (77)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.24<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.13<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80 (17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67 (22)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 (1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (2)<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1005511">rs1005511</ext-link><hr/></td><td rowspan="3" valign="top" align="center" colspan="1">Intron 2<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">57123232<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.33<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.26<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">208 (46)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">124 (43)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.43<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.7<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">194 (43)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">137 (47)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52 (11)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (10)<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2508443">rs2508443</ext-link><hr/></td><td rowspan="3" valign="top" align="center" colspan="1">Intron 6<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">57134568<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.4<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.37<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">180 (38)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">104 (34)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.27<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.47<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">211 (45)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">157 (51)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">78 (17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48 (16)<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link><hr/></td><td rowspan="3" valign="top" align="center" colspan="1">Intron 6<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">57134901<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.4<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.27<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">179 (38)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">103 (33)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.27<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.44<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">211 (45)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">157 (51)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80 (17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50 (16)<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4926">rs4926</ext-link></td><td rowspan="3" valign="top" align="center" colspan="1">V480M&#x02028;(Exon 8)</td><td rowspan="3" valign="top" align="center" colspan="1">57138565</td><td rowspan="3" valign="top" align="center" colspan="1">0.27</td><td rowspan="3" valign="top" align="center" colspan="1">0.52</td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">252 (54)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">167 (54)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.14</td><td rowspan="3" valign="top" align="center" colspan="1">0.36</td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">172 (37)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">124 (40)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA</td><td valign="top" align="center" rowspan="1" colspan="1">47 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (6)</td></tr></tbody></table><table-wrap-foot><p>The seven single-nucleotide polymorphisms (SNPs) were tested for association with age-related macular degeneration (AMD) in the Mayo subjects and none was observed.</p></table-wrap-foot></table-wrap></sec><sec><title>Linkage disequilibrium</title><p>To verify that our genotyping results were similar to other Caucasian populations genotyped across <italic>SERPING1</italic>, we compared the pattern of linkage disequilibrium (LD) in the Mayo subjects to the international <ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org/">HapMap</ext-link> Caucasian subjects using <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview/">Haploview</ext-link> [<xref ref-type="bibr" rid="r48">48</xref>,<xref ref-type="bibr" rid="r51">51</xref>]. Moderate to high LD was observed across the <italic>SERPING1</italic> locus and a similar pattern was present in the Mayo subjects and <ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org/">HapMap</ext-link> Caucasian subjects (<xref ref-type="fig" rid="f1">Figure 1</xref>). The similar pattern of LD further supports the accuracy of genotyping of all seven SNPs in the Mayo subjects.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Linkage disequilibrium (LD) across the <italic>SERPING1</italic> locus in <ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org/">HapMap</ext-link> (left) and Mayo subjects (right). A similar LD pattern was observed for the two independent groups of Caucasian subjects. Numbers in the squares represent r<sup>2</sup> estimates, while colors represent D&#x02019; estimates (from none or white, to complete or red).</p></caption><graphic xlink:href="mv-v15-200-f1"/></fig></sec><sec><title>Haplotype studies</title><p>Comparison of haplotypes across the <italic>SERPING1</italic> locus in the Mayo subjects and the international <ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org/">HapMap</ext-link> Caucasian subjects showed a similar distribution of haplotypes (<xref ref-type="table" rid="t3">Table 3</xref>). Further, no haplotype was associated with AMD in the Mayo subjects (p=0.14&#x02013;0.97, <xref ref-type="table" rid="t3">Table 3</xref>). A 3-SNP sliding window analysis did not reveal association between the <italic>SERPING1</italic> haplotypes and AMD (p=0.13&#x02013;0.67).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title><italic>SERPING1</italic> haplotypes observed in the Mayo subjects and Caucasian subjects from the International <ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org/">HapMap</ext-link> project</title></caption><table frame="hsides" rules="groups"><col width="73" span="1"/><col width="57" span="1"/><col width="53" span="1"/><col width="49" span="1"/><col width="113" span="1"/><col width="108" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Haplotype</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">Frequency</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Association with AMD in Mayo subjects</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">HapMap<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Mayo cases<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Mayo controls<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Odds ratio (95% CI)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Simulated p-value<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GTCGTAG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.395<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.347<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.368<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.436<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CCCAGGG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.325<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.320<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.317<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.064 (0.828&#x02013;1.368)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.966<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CTCGGGA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.071<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.127<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.102<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.330 (0.934&#x02013;1.894)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.137<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">CCCGGGA</td><td valign="top" align="center" rowspan="1" colspan="1">0.062</td><td valign="top" align="center" rowspan="1" colspan="1">0.098</td><td valign="top" align="center" rowspan="1" colspan="1">0.120</td><td valign="top" align="center" rowspan="1" colspan="1">0.902 (0.642&#x02013;1.267)</td><td valign="top" align="center" rowspan="1" colspan="1">0.189</td></tr></tbody></table><table-wrap-foot><p>Haplotypes with a frequency of 5% or higher are shown. The single-nucleotide polymorphism (SNP) order (left to right) is the same as in <xref ref-type="table" rid="t1">Table 1</xref>. Haplotypes across the <italic>SERPING1</italic> locus were tested for association with age-related macular degeneration (AMD) in the Mayo subjects and none was observed.</p></table-wrap-foot></table-wrap></sec><sec><title>Replication study</title><p>Given the demonstrated accuracy of genotyping, we sought to determine if the absence of association could be due to a type II error arising in the Mayo subject group. The most highly associated variant in the previous report (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link>) was genotyped on 1,541 AREDS subjects (<xref ref-type="table" rid="t4">Table 4</xref>) and no association with AMD was observed (p=0.45).</p><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Comparison of the association observed between AMD and the <italic>SERPING1</italic> variant <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> in four subject groups</title></caption><table frame="hsides" rules="groups"><col width="122" span="1"/><col width="69" span="1"/><col width="50" span="1"/><col width="51" span="1"/><col width="50" span="1"/><col width="59" span="1"/><col width="50" span="1"/><col width="59" span="1"/><col width="50" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Subject group (genotyping platform)</bold></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Mayo subjects (TaqMan)</bold></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><bold>AREDS subjects (TaqMan)</bold></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Ennis et al. (UK) subjects (Illumina)</bold></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Ennis et al. (US) subjects (TaqMan)</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><bold>Subjects</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Case</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Control</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Case</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Control</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Case</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Control</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Case</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Control</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">No. of participants<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">470<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">310<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1221<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">295<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">479<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">479<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">248<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">252<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="col" rowspan="1" colspan="1">Allele count (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">569 (61)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">363 (59)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1435 (59)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">357 (61)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">597 (63)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">500 (52)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">322 (65)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">282 (56)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">371 (39)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">257 (41)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1007 (41)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">233 (39)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">355 (37)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">454 (48)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">174 (35)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">222 (44)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="col" rowspan="1" colspan="1">Genotype count (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">179 (38)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">103 (33)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">436 (36)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">115 (39)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">191 (40)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">132 (28)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">100 (40)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">79 (31)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">211 (45)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">157 (51)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">563 (46)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">127 (43)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">215 (45)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">236 (50)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">122 (49)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">124 (49)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80 (17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50 (16)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">222 (18)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53 (18)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">70 (15)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">109 (23)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26 (11)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">49 (19)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="col" rowspan="1" colspan="1">P-values<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Allele<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.46<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.41<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.4E-06<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0037<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Genotype</td><td valign="top" align="center" rowspan="1" colspan="1">0.44</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">0.45</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">4.0E-05</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">0.0080</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>Allele frequencies and genotype counts are shown for all four subject groups genotyped on <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> to date. The differences between cases and controls in the Mayo and AREDS subjects did not reach statistical significance.</p></table-wrap-foot></table-wrap></sec><sec><title>AMD subtype analysis</title><p>To determine if the absence of association between AMD and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> could be due to differences in the distribution of AMD subtypes in the different subject groups, we stratified the AMD subjects into early AMD, primary geographic atrophy, and exudation. Subgroup analysis using the seven tag-SNPs genotyped on the Mayo subjects revealed no evidence for association with any AMD subtype (early AMD, p=0.43&#x02013;0.88; geographic atrophy, p=0.13&#x02013;0.96; exudation, p=0.05&#x02013;0.66). Similarly, no association between <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> genotypes and AMD subtypes were observed in the AREDS subjects (p=0.17&#x02013;0.97). No haplotype was consistently associated with any AMD subtype (p=0.09&#x02013;0.98).</p></sec><sec><title>Interaction with other genetic risks for AMD</title><p>We further sought to determine if the absence of an effect of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> on AMD risk might be explained by differences between modifiable risk factors and other genetic risks for AMD in the Mayo subjects. We observed no interaction between smoking categorized as ever or never and <italic>SERPING1</italic> SNPs using logistic regression (p=0.25&#x02013;0.52). We also found no interaction (p=0.68&#x02013;0.98) between <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> and other major genetics risks for AMD including complement factor H (<italic>CFH</italic>, Y402H), <italic>ARMS2/HTRA1</italic> (tagging SNP A69S), complement components <italic>CFB/C2</italic> (<italic>CFB</italic>, L9H; <italic>C2</italic>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=547154">rs547154</ext-link>), and <italic>C3</italic> (R102G and P314L).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We were unable to replicate the previously reported association between <italic>SERPING1</italic> and AMD using two independent groups of subjects [<xref ref-type="bibr" rid="r13">13</xref>]. Our study comprehensively assessed common variation in <italic>SERPING1</italic> and specifically the SNP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link>) most highly associated with AMD in the previous study [<xref ref-type="bibr" rid="r13">13</xref>].</p><p>The previous study observed several SNPs (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2244169">rs2244169</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511990">rs2511990</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2509897">rs2509897</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511988">rs2511988</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1005510">rs1005510</ext-link>) across <italic>SERPING1</italic> that were associated with AMD [<xref ref-type="bibr" rid="r13">13</xref>]. We genotyped three of these SNP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2509897">rs2509897</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511990">rs2511990</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link>) and observed no association with AMD. Although some investigators have felt that observing association from SNPs near the initial disease associated SNP provides additional support for the association, we have observed otherwise [<xref ref-type="bibr" rid="r11">11</xref>]. This situation arises secondary to linkage disequilibrium and supports accurate genotyping, but does not protect against a type I error [<xref ref-type="bibr" rid="r11">11</xref>].</p><p>We recognize that a particular group of subjects may miss a valid association (type II error) or show false association (type I error). Several causes for such observations exist including invalid genotyping, population stratification, non-random sampling of the underlying population, and differences in non-randomized features of the cases and controls such as disease subtypes. For these reasons, we validated the genotyping with a second independent assay, studied two independent populations, and extensively studied the disease subgroups and similarities between our Caucasian populations and those genotyped elsewhere (<ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org/">HapMap</ext-link>). All of these analyses supported the validity of our study and failed to provide evidence for an effect of <italic>SERPING1</italic> SNPs on AMD. Genotyping of additional groups of subjects will be required to determine if <italic>SERPING1</italic> SNPs are associated with AMD in selected populations. Nonetheless, a major effect on AMD is unlikely.</p><p>Genotyping errors can reduce power and are thus of particular concern in a study that fails to replicate a previous observation. The previous study used an Illumina BeadChip platform in one group of subjects and an assay on demand TaqMan method in a second independent group of subjects [<xref ref-type="bibr" rid="r13">13</xref>] for genotyping <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2511989">rs2511989</ext-link> (<xref ref-type="table" rid="t4">Table 4</xref>). Eight additional SNPs were genotyped using a third (KBioscience, Hoddesdon, UK) platform. Thus, genotyping errors seem unlikely to have caused a type I error in the previous report. We employed the same genotyping assay (TaqMan, Foster City, CA) used on one of their subject groups on both of our groups of subjects and performed DNA sequencing to confirm genotyping results. Genotyping problems seem unlikely to explain the differences between the studies.</p><p><italic>SERPING1</italic> is expressed in the neural retina, RPE, and choroid of humans [<xref ref-type="bibr" rid="r13">13</xref>] and is likely to play a role in regulating the complement system in the eye. Mutations in <italic>SERPING1</italic> cause hereditary angioedema, but there is no known phenotypic overlap with AMD such as had been established with atypical hemolytic uremic syndrome or glomerulonephritis arising in patients with mutations in <italic>CFH</italic> [<xref ref-type="bibr" rid="r52">52</xref>]. In summary, we were unable to replicate the association between genetic variation in <italic>SERPING1</italic> and AMD in two large and well characterized Caucasian subject groups and no compelling biologic evidence is available to support a role for the C1 inhibitor in AMD at this time.</p></sec></body><back><ack><title>Acknowledgments</title><p>The research was supported by EY014467, the Foundation Fighting Blindness, Owing Mills, MD, the American Health Assistance Foundation, Clarksburg, MD, unrestricted departmental grants from Research to Prevent Blindness, New York, NY, Mayo Foundation, Rochester, MN, and Seoul National University Bundang Hospital, Seoul, Korea.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>DS</given-names></name><name><surname>O'Colmain</surname><given-names>BJ</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>B</given-names></name><name><surname>Tomany</surname><given-names>SC</given-names></name><name><surname>McCarty</surname><given-names>C</given-names></name><name><surname>de Jong</surname><given-names>PT</given-names></name><name><surname>Nemesure</surname><given-names>B</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Kempen</surname><given-names>J</given-names></name><collab>Eye Diseases Prevalence Research Group.</collab></person-group><article-title>Prevalence of age-related macular degeneration in the United States.</article-title><source>Arch Ophthalmol</source><year>2004</year><volume>122</volume><fpage>564</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">15078675</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newsome</surname><given-names>DA</given-names></name><name><surname>Hewitt</surname><given-names>AT</given-names></name><name><surname>Huh</surname><given-names>W</given-names></name><name><surname>Robey</surname><given-names>PG</given-names></name><name><surname>Hassell</surname><given-names>JR</given-names></name></person-group><article-title>Detection of specific extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body.</article-title><source>Am J Ophthalmol</source><year>1987</year><volume>104</volume><fpage>373</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">3310642</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LV</given-names></name><name><surname>Leitner</surname><given-names>WP</given-names></name><name><surname>Staples</surname><given-names>MK</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name></person-group><article-title>Complement activation and inflammatory processes in Drusen formation and age related macular degeneration.</article-title><source>Exp Eye Res</source><year>2001</year><volume>73</volume><fpage>887</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11846519</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Ritter</surname><given-names>R</given-names><suffix>3rd</suffix></name><name><surname>Abel</surname><given-names>KJ</given-names></name><name><surname>Manning</surname><given-names>A</given-names></name><name><surname>Panhuysen</surname><given-names>C</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name></person-group><article-title>Complement factor H polymorphism and age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>421</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15761121</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Olson</surname><given-names>LM</given-names></name><name><surname>Gallins</surname><given-names>P</given-names></name><name><surname>Spencer</surname><given-names>KL</given-names></name><name><surname>Kwan</surname><given-names>SY</given-names></name><name><surname>Noureddine</surname><given-names>M</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Schnetz-Boutaud</surname><given-names>N</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Complement factor H variant increases the risk of age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>419</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15761120</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>RJ</given-names></name><name><surname>Zeiss</surname><given-names>C</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Tsai</surname><given-names>JY</given-names></name><name><surname>Sackler</surname><given-names>RS</given-names></name><name><surname>Haynes</surname><given-names>C</given-names></name><name><surname>Henning</surname><given-names>AK</given-names></name><name><surname>SanGiovanni</surname><given-names>JP</given-names></name><name><surname>Mane</surname><given-names>SM</given-names></name><name><surname>Mayne</surname><given-names>ST</given-names></name><name><surname>Bracken</surname><given-names>MB</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Barnstable</surname><given-names>C</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name></person-group><article-title>Complement factor H polymorphism in age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>385</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15761122</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>B</given-names></name><name><surname>Merriam</surname><given-names>JE</given-names></name><name><surname>Zernant</surname><given-names>J</given-names></name><name><surname>Hancox</surname><given-names>LS</given-names></name><name><surname>Taiber</surname><given-names>AJ</given-names></name><name><surname>Gehrs</surname><given-names>K</given-names></name><name><surname>Cramer</surname><given-names>K</given-names></name><name><surname>Neel</surname><given-names>J</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Barile</surname><given-names>GR</given-names></name><name><surname>Smith</surname><given-names>RT</given-names></name></person-group><article-title>AMD Genetics Clinical Study Group, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>458</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16518403</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maller</surname><given-names>JB</given-names></name><name><surname>Fagerness</surname><given-names>JA</given-names></name><name><surname>Reynolds</surname><given-names>RC</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Seddon</surname><given-names>JM</given-names></name></person-group><article-title>Variation in complement factor 3 is associated with risk of age-related macular degeneration.</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>1200</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">17767156</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Sepp</surname><given-names>T</given-names></name><name><surname>Matharu</surname><given-names>BK</given-names></name><name><surname>Khan</surname><given-names>JC</given-names></name><name><surname>Thurlby</surname><given-names>DA</given-names></name><name><surname>Shahid</surname><given-names>H</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>AF</given-names></name><name><surname>Armbrecht</surname><given-names>AM</given-names></name><name><surname>Dhillon</surname><given-names>B</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Redmond</surname><given-names>E</given-names></name><name><surname>Bird</surname><given-names>AC</given-names></name><name><surname>Moore</surname><given-names>AT</given-names></name><collab>Genetic Factors in AMD Study Group.</collab></person-group><article-title>Complement C3 variant and the risk of age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>553</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17634448</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>KL</given-names></name><name><surname>Olson</surname><given-names>LM</given-names></name><name><surname>Anderson</surname><given-names>BM</given-names></name><name><surname>Schnetz-Boutaud</surname><given-names>N</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Gallins</surname><given-names>P</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name></person-group><article-title>C3 R102G polymorphism increases risk of age-related macular degeneration.</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><fpage>1821</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">18325906</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Fridley</surname><given-names>BL</given-names></name><name><surname>James</surname><given-names>KM</given-names></name><name><surname>Sharma</surname><given-names>AS</given-names></name><name><surname>Cunningham</surname><given-names>JM</given-names></name><name><surname>Tosakulwong</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of clustering and genotype distribution for replication in genome wide association studies: the age-related eye disease study.</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e3813</fpage><pub-id pub-id-type="pmid">19043567</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Malek</surname><given-names>G</given-names></name></person-group><article-title>Molecular genetics of AMD and current animal models.</article-title><source>Angiogenesis</source><year>2007</year><volume>10</volume><fpage>119</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17372852</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ennis</surname><given-names>S</given-names></name><name><surname>Jomary</surname><given-names>C</given-names></name><name><surname>Mullins</surname><given-names>R</given-names></name><name><surname>Cree</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Macleod</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>E</given-names></name><name><surname>Lotery</surname><given-names>A</given-names></name></person-group><article-title>Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study.</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1828</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18842294</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goverdhan</surname><given-names>SV</given-names></name><name><surname>Howell</surname><given-names>MW</given-names></name><name><surname>Mullins</surname><given-names>RF</given-names></name><name><surname>Osmond</surname><given-names>C</given-names></name><name><surname>Hodgkins</surname><given-names>PR</given-names></name><name><surname>Self</surname><given-names>J</given-names></name><name><surname>Avery</surname><given-names>K</given-names></name><name><surname>Lotery</surname><given-names>AJ</given-names></name></person-group><article-title>Association of HLA class I and class II polymorphisms with age-related macular degeneration.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>1726</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15851575</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Braun</surname><given-names>TA</given-names></name><name><surname>Russell</surname><given-names>SR</given-names></name><name><surname>Kuehn</surname><given-names>MH</given-names></name><name><surname>Lotery</surname><given-names>AJ</given-names></name><name><surname>Moore</surname><given-names>PA</given-names></name><name><surname>Eastman</surname><given-names>CG</given-names></name><name><surname>Casavant</surname><given-names>TL</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name></person-group><article-title>Missense variations in the fibulin 5 gene and age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>346</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15269314</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Ishibashi</surname><given-names>K</given-names></name><name><surname>Tsukahara</surname><given-names>Y</given-names></name><name><surname>Negi</surname><given-names>A</given-names></name></person-group><article-title>Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>1101</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18326737</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fagerness</surname><given-names>JA</given-names></name><name><surname>Maller</surname><given-names>JB</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Reynolds</surname><given-names>RC</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Seddon</surname><given-names>JM</given-names></name></person-group><article-title>Variation near complement factor I is associated with risk of advanced AMD.</article-title><source>Eur J Hum Genet</source><year>2009</year><volume>17</volume><fpage>100</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">18685559</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>MM</given-names></name><name><surname>Manwaring</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Rochtchina</surname><given-names>E</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Sue</surname><given-names>CM</given-names></name></person-group><article-title>Mitochondrial DNA haplogroups and age-related maculopathy.</article-title><source>Arch Ophthalmol</source><year>2007</year><volume>125</volume><fpage>1235</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">17846364</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuo</surname><given-names>J</given-names></name><name><surname>Ning</surname><given-names>B</given-names></name><name><surname>Bojanowski</surname><given-names>CM</given-names></name><name><surname>Lin</surname><given-names>ZN</given-names></name><name><surname>Ross</surname><given-names>RJ</given-names></name><name><surname>Reed</surname><given-names>GF</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Kadlubar</surname><given-names>FF</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name></person-group><article-title>Synergic effect of polymorphisms in ERCC6 5&#x02032; flanking region and complement factor H on age-related macular degeneration predisposition.</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>9256</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">16754848</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Tuo</surname><given-names>J</given-names></name><name><surname>Bojanowski</surname><given-names>CM</given-names></name><name><surname>Csaky</surname><given-names>KG</given-names></name><name><surname>Green</surname><given-names>WR</given-names></name></person-group><article-title>Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration.</article-title><source>Histol Histopathol</source><year>2005</year><volume>20</volume><fpage>857</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15944936</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Shankar</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Bray</surname><given-names>MS</given-names></name><name><surname>Couper</surname><given-names>DJ</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Sharrett</surname><given-names>AR</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name></person-group><article-title>Apolipoprotein E gene and early age-related maculopathy: the Atherosclerosis Risk in Communities Study.</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>255</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16406547</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>I</given-names></name><name><surname>Hussain</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>N</given-names></name><name><surname>Das</surname><given-names>T</given-names></name><name><surname>Pathangay</surname><given-names>A</given-names></name><name><surname>Mathai</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>A</given-names></name><name><surname>Nutheti</surname><given-names>R</given-names></name><name><surname>Nirmalan</surname><given-names>PK</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name></person-group><article-title>Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>3729</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">16936080</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baird</surname><given-names>PN</given-names></name><name><surname>Richardson</surname><given-names>AJ</given-names></name><name><surname>Robman</surname><given-names>LD</given-names></name><name><surname>Dimitrov</surname><given-names>PN</given-names></name><name><surname>Tikellis</surname><given-names>G</given-names></name><name><surname>McCarty</surname><given-names>CA</given-names></name><name><surname>Guymer</surname><given-names>RH</given-names></name></person-group><article-title>Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD).</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><fpage>337</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16453339</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>SY</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name></person-group><article-title>Joint effects of smoking history and APOE genotypes in age-related macular degeneration.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>941</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16288198</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Klaver</surname><given-names>C</given-names></name><name><surname>Saunders</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>E</given-names></name><name><surname>De La Paz</surname><given-names>M</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Small</surname><given-names>K</given-names></name><name><surname>Udar</surname><given-names>N</given-names></name><name><surname>Ong</surname><given-names>J</given-names></name><name><surname>Chalukya</surname><given-names>M</given-names></name><name><surname>Nesburn</surname><given-names>A</given-names></name><name><surname>Kenney</surname><given-names>C</given-names></name><name><surname>Domurath</surname><given-names>R</given-names></name><name><surname>Hogan</surname><given-names>M</given-names></name><name><surname>Mah</surname><given-names>T</given-names></name><name><surname>Conley</surname><given-names>Y</given-names></name><name><surname>Ferrell</surname><given-names>R</given-names></name><name><surname>Weeks</surname><given-names>D</given-names></name><name><surname>de Jong</surname><given-names>PT</given-names></name><name><surname>van Duijn</surname><given-names>C</given-names></name><name><surname>Haines</surname><given-names>J</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><name><surname>Gorin</surname><given-names>M</given-names></name></person-group><article-title>A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy.</article-title><source>Ophthalmic Genet</source><year>2002</year><volume>23</volume><fpage>209</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12567264</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klaver</surname><given-names>CC</given-names></name><name><surname>Kliffen</surname><given-names>M</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>van Broeckhoven</surname><given-names>C</given-names></name><name><surname>de Jong</surname><given-names>PT</given-names></name></person-group><article-title>Genetic association of apolipoprotein E with age-related macular degeneration.</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>200</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9634502</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Fridley</surname><given-names>BL</given-names></name><name><surname>James</surname><given-names>KM</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Othman</surname><given-names>M</given-names></name><name><surname>Branham</surname><given-names>K</given-names></name><name><surname>Iyengar</surname><given-names>SK</given-names></name><name><surname>Sivakumaran</surname><given-names>TA</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Tosakulwong</surname><given-names>N</given-names></name></person-group><article-title>Toll-like receptor polymorphisms and age-related macular degeneration.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>1652</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18385087</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Stratton</surname><given-names>C</given-names></name><name><surname>Francis</surname><given-names>PJ</given-names></name><name><surname>Kleinman</surname><given-names>ME</given-names></name><name><surname>Tan</surname><given-names>PL</given-names></name><name><surname>Gibbs</surname><given-names>D</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Constantine</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Davey</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Hau</surname><given-names>VS</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Harmon</surname><given-names>J</given-names></name><name><surname>Buehler</surname><given-names>J</given-names></name><name><surname>Pearson</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Kaminoh</surname><given-names>Y</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Zabriskie</surname><given-names>NA</given-names></name><name><surname>Bernstein</surname><given-names>PS</given-names></name><name><surname>Cho</surname><given-names>W</given-names></name><name><surname>Schwager</surname><given-names>A</given-names></name><name><surname>Hinton</surname><given-names>DR</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name><name><surname>Hamon</surname><given-names>SC</given-names></name><name><surname>Simmons</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Campochiaro</surname><given-names>B</given-names></name><name><surname>Sunness</surname><given-names>JS</given-names></name><name><surname>Campochiaro</surname><given-names>P</given-names></name><name><surname>Jorde</surname><given-names>L</given-names></name><name><surname>Parmigiani</surname><given-names>G</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name><name><surname>Katsanis</surname><given-names>N</given-names></name><name><surname>Ambati</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group><article-title>Toll-like receptor 3 and geographic atrophy in age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1456</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18753640</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zareparsi</surname><given-names>S</given-names></name><name><surname>Buraczynska</surname><given-names>M</given-names></name><name><surname>Branham</surname><given-names>KE</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Eng</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Pawar</surname><given-names>H</given-names></name><name><surname>Yashar</surname><given-names>BM</given-names></name><name><surname>Moroi</surname><given-names>SE</given-names></name><name><surname>Lichter</surname><given-names>PR</given-names></name><name><surname>Petty</surname><given-names>HR</given-names></name><name><surname>Richards</surname><given-names>JE</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Elner</surname><given-names>VM</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><article-title>Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration.</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><fpage>1449</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15829498</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><name><surname>Fritsche</surname><given-names>LG</given-names></name><name><surname>Keilhauer</surname><given-names>CN</given-names></name><name><surname>Lichtner</surname><given-names>P</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>BH</given-names></name></person-group><article-title>Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><fpage>3227</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16174643</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jakobsdottir</surname><given-names>J</given-names></name><name><surname>Conley</surname><given-names>YP</given-names></name><name><surname>Weeks</surname><given-names>DE</given-names></name><name><surname>Mah</surname><given-names>TS</given-names></name><name><surname>Ferrell</surname><given-names>RE</given-names></name><name><surname>Gorin</surname><given-names>MB</given-names></name></person-group><article-title>Susceptibility genes for age-related maculopathy on chromosome 10q26.</article-title><source>Am J Hum Genet</source><year>2005</year><volume>77</volume><fpage>389</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">16080115</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>DZ</given-names></name></person-group><article-title>An immunologic study on age-related macular degeneration.</article-title><source>Yen Ko Hsueh Pao</source><year>1993</year><volume>9</volume><fpage>113</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">8168604</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Penfold</surname><given-names>PL</given-names></name><name><surname>Provis</surname><given-names>JM</given-names></name><name><surname>Furby</surname><given-names>JH</given-names></name><name><surname>Gatenby</surname><given-names>PA</given-names></name><name><surname>Billson</surname><given-names>FA</given-names></name></person-group><article-title>Autoantibodies to retinal astrocytes associated with age-related macular degeneration.</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>1990</year><volume>228</volume><fpage>270</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">2193850</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Umeda</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>MT</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Ono</surname><given-names>F</given-names></name><name><surname>Mizota</surname><given-names>A</given-names></name><name><surname>Terao</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name></person-group><article-title>Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis).</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>1683</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16099945</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Ohbayashi</surname><given-names>M</given-names></name><name><surname>Nugent</surname><given-names>AK</given-names></name><name><surname>Ramchand</surname><given-names>K</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name><name><surname>Chau</surname><given-names>KY</given-names></name><name><surname>Bunce</surname><given-names>C</given-names></name><name><surname>Webster</surname><given-names>A</given-names></name><name><surname>Bird</surname><given-names>AC</given-names></name><name><surname>Ono</surname><given-names>SJ</given-names></name><name><surname>Chong</surname><given-names>V</given-names></name></person-group><article-title>Circulating anti-retinal antibodies as immune markers in age-related macular degeneration.</article-title><source>Immunology</source><year>2005</year><volume>115</volume><fpage>422</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15946260</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hollyfield</surname><given-names>JG</given-names></name><name><surname>Bonilha</surname><given-names>VL</given-names></name><name><surname>Rayborn</surname><given-names>ME</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Shadrach</surname><given-names>KG</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Ufret</surname><given-names>RL</given-names></name><name><surname>Salomon</surname><given-names>RG</given-names></name><name><surname>Perez</surname><given-names>VL</given-names></name></person-group><article-title>Oxidative damage-induced inflammation initiates age-related macular degeneration.</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>194</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18223656</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Lukas</surname><given-names>TJ</given-names></name><name><surname>Neufeld</surname><given-names>AH</given-names></name></person-group><article-title>The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration.</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e2339</fpage><pub-id pub-id-type="pmid">18523633</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Frank</surname><given-names>MM</given-names></name></person-group><article-title>Complement 1 inhibitor is a regulator of the alternative complement pathway.</article-title><source>J Exp Med</source><year>2001</year><volume>194</volume><fpage>1609</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11733575</pub-id></citation></ref><ref id="r39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name></person-group><article-title>Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease.</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><fpage>2281</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10679061</pub-id></citation></ref><ref id="r40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>AE</given-names><suffix>3rd</suffix></name><name><surname>Mejia</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name></person-group><article-title>Biological activities of C1 inhibitor.</article-title><source>Mol Immunol</source><year>2008</year><volume>45</volume><fpage>4057</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18674818</pub-id></citation></ref><ref id="r41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pappalardo</surname><given-names>E</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Duponchel</surname><given-names>C</given-names></name><name><surname>Carugati</surname><given-names>A</given-names></name><name><surname>Choquet</surname><given-names>S</given-names></name><name><surname>Agostoni</surname><given-names>A</given-names></name><name><surname>Tosi</surname><given-names>M</given-names></name></person-group><article-title>Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema.</article-title><source>J Allergy Clin Immunol</source><year>2000</year><volume>106</volume><fpage>1147</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11112899</pub-id></citation></ref><ref id="r42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cumming</surname><given-names>SA</given-names></name><name><surname>Halsall</surname><given-names>DJ</given-names></name><name><surname>Ewan</surname><given-names>PW</given-names></name><name><surname>Lomas</surname><given-names>DA</given-names></name></person-group><article-title>The effect of sequence variations within the coding region of the C1 inhibitor gene on disease expression and protein function in families with hereditary angio-oedema.</article-title><source>J Med Genet</source><year>2003</year><volume>40</volume><fpage>e114</fpage><pub-id pub-id-type="pmid">14569137</pub-id></citation></ref><ref id="r43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanch</surname><given-names>A</given-names></name><name><surname>Roche</surname><given-names>O</given-names></name><name><surname>Lopez-Granados</surname><given-names>E</given-names></name><name><surname>Fontan</surname><given-names>G</given-names></name><name><surname>Lopez-Trascasa</surname><given-names>M</given-names></name></person-group><article-title>Detection of C1 inhibitor (SERPING1/C1NH) mutations in exon 8 in patients with hereditary angioedema: evidence for 10 novel mutations.</article-title><source>Hum Mutat</source><year>2002</year><volume>20</volume><fpage>405</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12402344</pub-id></citation></ref><ref id="r44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>ML</given-names></name><name><surname>Schultz</surname><given-names>DW</given-names></name><name><surname>Edwards</surname><given-names>A</given-names></name><name><surname>Matise</surname><given-names>TC</given-names></name><name><surname>Rust</surname><given-names>K</given-names></name><name><surname>Berselli</surname><given-names>CB</given-names></name><name><surname>Trzupek</surname><given-names>K</given-names></name><name><surname>Weleber</surname><given-names>RG</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Wirtz</surname><given-names>MK</given-names></name><name><surname>Acott</surname><given-names>TS</given-names></name></person-group><article-title>Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q.</article-title><source>Arch Ophthalmol</source><year>1998</year><volume>116</volume><fpage>1082</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9715689</pub-id></citation></ref><ref id="r45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Majewski</surname><given-names>J</given-names></name><name><surname>Schultz</surname><given-names>DW</given-names></name><name><surname>Weleber</surname><given-names>RG</given-names></name><name><surname>Schain</surname><given-names>MB</given-names></name><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Matise</surname><given-names>TC</given-names></name><name><surname>Acott</surname><given-names>TS</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><article-title>Age-related macular degeneration&#x02013;a genome scan in extended families.</article-title><source>Am J Hum Genet</source><year>2003</year><volume>73</volume><fpage>540</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12900797</pub-id></citation></ref><ref id="r46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Magli</surname><given-names>YL</given-names></name><name><surname>Segal</surname><given-names>P</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Hubbard</surname><given-names>L</given-names></name></person-group><article-title>The Wisconsin age-related maculopathy grading system.</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>1128</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">1843453</pub-id></citation></ref><ref id="r47"><label>47</label><citation citation-type="journal"><article-title>A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.</article-title><source>Arch Ophthalmol</source><year>2001</year><volume>119</volume><fpage>1417</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">11594942</pub-id></citation></ref><ref id="r48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><collab>The International HapMap Project</collab></person-group><article-title>The International HapMap Consortium</article-title><source>Nature</source><year>2003</year><volume>426</volume><fpage>789</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">14685227</pub-id></citation></ref><ref id="r49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Eberle</surname><given-names>MA</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Kruglyak</surname><given-names>L</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name></person-group><article-title>Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><fpage>106</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">14681826</pub-id></citation></ref><ref id="r50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Rowland</surname><given-names>CM</given-names></name><name><surname>Tines</surname><given-names>DE</given-names></name><name><surname>Jacobson</surname><given-names>RM</given-names></name><name><surname>Poland</surname><given-names>GA</given-names></name></person-group><article-title>Score tests for association between traits and haplotypes when linkage phase is ambiguous.</article-title><source>Am J Hum Genet</source><year>2002</year><volume>70</volume><fpage>425</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11791212</pub-id></citation></ref><ref id="r51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="r52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mullins</surname><given-names>RF</given-names></name><name><surname>Aptsiauri</surname><given-names>N</given-names></name><name><surname>Hageman</surname><given-names>GS</given-names></name></person-group><article-title>Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis.</article-title><source>Eye</source><year>2001</year><volume>15</volume><fpage>390</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11450763</pub-id></citation></ref></ref-list></back></article> 